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Because of the increasing incidence of obesity worldwide, the molecular 
mechanisms controlling adipogenesis have become a critical area of research (1).  Studies 
related to adipogenesis have led to the identification of genes involved sequentially in the 
differentiation of fat cells, such as C/EBPβ, C/EBPδ, C/EBPα, and PPARγ (2, 3).  This 
thesis focuses on the regulation of the activity of CCAAT/Enhancer Binding Protein 
(C/EBP) β, an early inducer of adipogenesis, which mediates the transcriptional 
activation of C/EBPα and PPARγ.  Because C/EBPβ associates with the nuclear 
coactivator p300, which contains acetyltransferase activity (4), we hypothesized that 
C/EBPβ is acetylated and that acetylation of C/EBPβ may contribute to its role in 
adipogenesis.  This thesis investigates a model in which dynamic regulation of the 
acetylation of C/EBPβ contributes to its ability to mediate transcriptional activation of 
target genes associated with adipogenesis.  Our findings suggest that acetylation of 
C/EBPβ at lysine 39 contributes to adipogenesis and adipocyte function, thereby adding 
to our understanding of cellular mechanisms relating to obesity, and revealing potential 




Adipocytes and Adipogenesis 
 
Adipocytes, or fat cells, are derived from mesenchymal precursors and expand 
extensively after birth (2).  Collectively, fat is a tissue that has long been known to serve 
as an energy depot by storing triglycerides.  Recent observations demonstrate that 
adipose tissue is not just a passive storage organ.  Adipose tissue has the capacity not 
only for lipid transport and synthesis, but also for immune function and secretion of 
hormones such as leptin, which regulates appetite and metabolism, adiponectin, which 
increases sensitivity of target cells to insulin, and resistin, which increases resistance to 
insulin (1).  Cell culture models have been developed to study the molecular basis of 
adipogenesis, or adipose cell differentiation.  Two widely used cell lines are 3T3-L1 and 
3T3-F442A preadipocytes, which were derived from mouse embryo fibroblasts that 
accumulated triacylglycerol lipid droplets (5, 6). 
A variety of inducers can initiate the process of adipogenesis in confluent 
monolayers of preadipocyte fibroblasts.  The inducers include agents which increase 
cAMP levels, glucocorticoids and IGF-1.  In cultured cell models, an adipogenic 
“cocktail” that includes isobutylmethylxanthine (MIX), dexamethasone, and insulin, in 
the presence of fetal bovine serum (FBS), referred to here as “MDI Medium”, is often 
used to induce adipose conversion (3, 7).  MIX is a cAMP phosphodiesterase inhibitor 
which increases cellular cAMP (8, 9).  It was originally postulated that MIX is capable of 
inducing CCAAT/Enhancer Binding Protein (C/EBP) β expression, while dexamethasone 
activates C/EBPδ (8); the two C/EBP family members are important early inducers of 
adipogenesis (discussed in detail below) (3, 10).  It has also been reported that 
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dexamethasone, a potent synthetic glucocorticoid (3), increases C/EBPβ expression and 
potentiates transcriptional activation by C/EBPβ (11).  Since the C/EBPβ promoter 
contains C/EBP binding sites, the increase attributed to C/EBPβ may be at least partially 
due to indirect activation of C/EBPβ by C/EBPδ.  Insulin also increases C/EBPβ and 
C/EBPδ expression (12).  Fetal bovine serum likely provides other factors that favor 
adipogenesis, including growth hormone (GH).  GH has been found to be a necessary 
component in the adipose conversion of 3T3-F442A cells (13); when GH was immuno-
depleted from FBS, differentiation could not be induced in these cells (14).   
 
Transcription Factors Involved in Adipose Differentiation 
 
Transcriptional activation involves the regulation of genes by transcription factors 
that bind to the regulatory sequences of target genes.  Transcription via transcription 
factors is regulated on several levels, including:  the binding of transcription factors to 
target sites, post-translational modifications of transcription factors themselves, binding 
of coactivators and corepressors, and the location and post-translational modification 
state of histones (15).  This thesis will focus on one post-translational modification, 
acetylation, of the transcription factor C/EBPβ. 
Adipose differentiation involves the sequential activation of transcription factors.  
Two of these transcription factors, C/EBPβ and C/EBPδ, are induced early in 
preadipocyte conversion to adipocytes.  C/EBPβ and C/EBPδ initiate a cascade of 
transcription factors that includes C/EBPα and Peroxisome Proliferator-Activated Protein 
(PPAR) γ (16), two master regulators of adipogenesis (3).  Although these transcription 
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factors have functions outside of adipose differentiation, this thesis will focus on their 
roles in adipogenesis.   
 
PPARγ2 
PPARγ2, a nuclear hormone receptor that heterodimerizes with Retinoic acid-X-Receptor 
(RXR) α, binds and activates genes involved in adipogenesis, such as adipocyte Protein 2 
(aP2/) and PhosphoEnolPyruvate CarboxyKinase (PEPCK) (17, 18).  aP2 is a cytosolic 
fatty acid binding protein that is induced by fatty acids, and PEPCK is an enzyme 
involved in gluconeogenesis (3).  PPARγ2 is a splice variant of PPARγ1 that includes a 
different 5’ untranslated sequence in the gene and 30 more amino acids on its N-terminus 
(17).  The inducible inactivation of the PPARγ gene in mouse adipose tissue leads to 
progressive lipodystrophy in fat tissue, supporting a role for PPARγ in adipocyte 
maintenance (19).  PPARγ2 is expressed exclusively in adipose tissue, and ectopic 
PPARγ2 expression in NIH-3T3 and Swiss-3T3 cells promotes their differentiation to 
adipocytes (18, 20).   
 
C/ EBPα   
C/EBPα, the founding member of the C/EBP family of transcription factors, is expressed 
in liver, intestine and lung, as well as adipose tissue (3).  C/EBPα is involved in 
termination of mitotic clonal expansion, when cells synchronously reenter the cell cycle 
and undergo several rounds of mitosis, during adipose differentiation.  C/EBPα also 
mediates activation of adipocyte genes that encode aP2, glucose transporter (GLUT) 4, 
and Stearoyl-CoA Desaturase (SCD) 1, as well as autoactivation of C/EBPα (3).  GLUT4 
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encodes an insulin-responsive glucose transporter (21, 22), and SCD1 is involved in 
lipogenesis and the desaturation of saturated fatty acids (23).  Expression of antisense 
C/EBPα RNA in cells blocked expression of these genes, and also blocked accumulation 
of cytoplasmic triacylglycerol.  Rescue could be induced by expressing a complementary 
sense RNA (24).  When C/EBPα is overexpressed, it induces adipose differentiation, 
even in the absence of differentiation medium (25, 26).  C/EBPα knockout mice die 
shortly after birth due to severe hypoglycemia, which is most likely a consequence of 
reduced glycogen synthesis in the liver.  Moreover, hepatocytes and adipocytes also fail 
to accumulate lipids (27).  Interestingly, C/EBPα does not promote adipogenesis in 
PPARγ-deficient cells, but PPARγ does promote adipogenesis in C/EBPα-deficient cells, 
suggesting that, even though there is cross-regulation, PPARγ is both necessary and 
sufficient for adipogenesis (28-30).  It is interesting to note that C/EBPα -/- cells that 
have been induced to differentiate with PPARγ are extensively insulin resistant (28).  
This indicates that, although C/EBPα may not be necessary for adipose conversion in cell 
culture, it is still necessary for other functions such as insulin sensitivity.    
  
C/EBPδ 
C/EBPδ is expressed in adipose tissue, lung and intestine (29, 31, 32), as well as in 
osteoblasts (33), mammary cells (34), and hepatocytes (35, 36).  C/EBPδ (-/-) mice have 
normal white adipose tissue, but have reduced lipids in their brown adipose tissue, as well 
as reduced expression of Uncoupling Protein-1 (UPC1), important in thermoregulation 
(37).  Although C/EBPδ plays a role in adipose differentiation, C/EBPβ is reported to 
play a more prominent role, especially in the activation of PPARγ (38). 
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Inhibitory transcription factors  
Several key transcription factors can inhibit adipose differentiation.  On the C/EBPα 
promoter, it is thought that the C/EBP binding site is unavailable as a docking site until 
C/EBP Undifferentiated Protein (CUP) dislodges from the nearby CUP regulatory 
element (39).  C/EBP homologous Protein (CHOP), or C/EBPζ, heterodimerizes with 
C/EBP family members, but because it contains an altered DNA binding region, it can act 
as a dominant negative protein in adipocyte differentiation by interfering with C/EBPβ 
function (40, 41).  GATA2, which normally promotes haematopoiesis and urogenital 
development, binds to C/EBPs.  Forced expression of GATA2 inhibits the ability of 
C/EBPs to transactivate PPARγ, thus inhibiting adipogenesis (42).  The nuclear protein 
Eight Twenty-One (ETO), whose expression decreases during adipose differentiation, 
can inhibit C/EBPβ function through a direct interaction with C/EBPβ (43). 
 
C/EBPβ is an Early Inducer of Adipogenesis 
 
C/EBPβ is a transcription factor that is present in cells in three forms:  Full length 
Liver-enriched Activating Protein 1 (LAP1, residues 1-296) (44), LAP2 (residues 22-
296), and Liver Inhibitory Protein (LIP, residues 151-296).  LIP is a shorter form that 
lacks the N-terminal transactivation sequence and is inhibitory (45, 46).  
The N-terminal transcriptional activation domain of C/EBPβ, specifically amino 
acids 85-95, is thought to interact with the basal transcriptional machinery (47).  The N-
terminus is also known to interact with important coactivators, including p300 (4) and 
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CREB-Binding Protein (CBP) (48).  Further, unspecified residues in the N-terminal 
transcriptional activation domain interact with Silencing Mediator for Retinoid and 
Thyroid hormone receptors (SMRT), a corepressor complex with deacetylase properties 
(49), and residues 1-22 in C/EBPβ interact with the Swi/Snf complex, an ATP-dependent 
helicase complex responsible for chromatin remodeling (50).  The N-terminus is critical 
for transcriptional activation (51), perhaps because of its ability to interact with key 
coactivators or corepressors. 
As a basic-leucine zipper (B-Zip) protein, C/EBPβ also contains a C-terminal 
basic DNA-binding domain and a leucine zipper which mediates dimerization (3) (Fig. 
1.1).  The DNA-binding domain binds to the DNA sequence ATTGCGCAAT, or a 
variation of this consensus C/EBP sequence (31).  The leucine zipper is composed of five 
heptad repeats that assemble into a dimeric coiled-coiled structure.  This interaction is 
responsible for homodimerization as well as heterodimerization with other B-Zip 
transcription factors, particularly with other members of the C/EBP family.  The dimer 
interacts with DNA via the basic region, forming a “scissors-grip” arrangement (52).  
Dimerization is a prerequisite for binding of C/EBPβ to DNA (29, 52, 53).  Recent 
reports also indicate that phosphorylation of C/EBPβ (at T179/T188 or S184/T188) leads 
to a three-dimensional change in C/EBPβ that can regulate its dimerization (54).  When 
phosphorylation increases at these sites, both glutaraldehyde-induced crosslinking of 
dimers, as well as binding to DNA are also increased.  C/EBPβ also contains negative 
regulatory domains that are thought to mask its transcriptional activation domain (51, 55).  
It is postulated that inactive C/EBPβ is folded in such a way that the N- and C-termini are 

















and CDK2 RSK-2 CaMKII
 1  296
K133
T217
Fig. 1.1 mouse C/EBPβ
S64 (*)
Ras
= GH-responsive  
 
Fig 1.1.  Domains and phosphorylation sites within C/EBPβ. Diagram indicates the 
different domains of C/EBPβ.  Also indicated are phosphorylation sites within mouse 
C/EBPβ, and their respective kinases, as well as a SUMO site. (*) =indicate 
phosphorylation sites have been found to be phosphorylated in rat, and that are conserved 
in mouse. 
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activation domain inaccessible to regulatory elements because of its binding to negative 
regulatory domains.  When C/EBPβ is phosphorylated, it modulates the three-dimensional 
structure of C/EBPβ molecule so that the transcriptional activation domain is available for 
interaction with regulatory proteins. 
 
The role of C/EBPβ in adipose differentiation 
C/EBPβ is expressed in adipose, hepatic, and a variety of other tissues (31, 46, 56-60).  In 
hepatocytes, C/EBPβ promotes proliferation in response to Transforming Growth Factor 
(TGF) α (61, 62); hepatocytes in C/EBPβ (-/-) mice exhibit a reduced regenerative response 
(63).  C/EBPβ (-/-) mice also exhibit defects in the gluconeogenic pathway attributed to 
reduced PEPCK levels (64).  Keratinocytes from C/EBPβ (-/-) mice are resistant to 
carcinogen-induced skin tumor development (60), indicating a role for C/EBPβ in promoting 
their proliferation.  C/EBPβ (-/-) mice also have an increased susceptibility to infection, 
which is thought to be due to impairments in bacteria killing and cytotoxicity, although the 
mechanism is obscure (65).  Further, C/EBPβ plays an important role in the hematopoietic 
system (66) and female reproduction (67).  Although C/EBPβ plays many roles in a variety 
of cellular functions, this thesis will focus on the role of C/EBPβ in adipogenesis. 
C/EBPβ, which induces expression of C/EBPα and PPARγ, is an early component of 
the transcriptional cascade of adipogenesis (3).  In C/EBPβ (-/-) C/EBPδ (-/-) mice, a 
significant decrease in adipose tissue mass was observed, despite normal expression of 
C/EBPα and PPARγ (37).  Cells from C/EBPβ (-/-) mice exhibited a significant  
reduction in adipose differentiation (37), supporting a prominent role for  
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C/EBPβ in adipose differentiation, especially in the activation of PPARγ (38).  C/EBPβ (-
/-) neonates show no other gross physical changes.  However, about 35% die by about 24 
hrs after birth and females are infertile.  C/EBPβ (-/-) mice are also refractory to diet-
induced obesity, reflected in lower levels of blood triglycerides, free fatty acids, 
cholesterol, and hepatic triglyceride accumulation (68).   
Early studies indicate that overexpression of C/EBPβ in NIH-3T3 cells is not 
sufficient to induce adipogenesis, whereas expression of C/EBPα is sufficient (26).  
Ectopic expression of C/EBPβ in NIH-3T3 cells, along with MDI medium, can induce 
adipose differentiation (8, 38).  Further, adenoviral expression of C/EBPβ in C/EBPβ(-/-) 
murine embryonic fibroblasts (MEFs), coupled with the addition of MDI medium, 
promoted expression of adipocyte markers in these cells (69).  In 3T3-L1 cells, Yeh et al. 
observed that overexpression of C/EBPβ led to adipocyte differentiation, even in the 
absence of hormonal stimulation (8). 
After addition of MDI medium, preadipocytes undergo several rounds of mitotic 
clonal expansion, which are thought to be necessary for differentiation to progress (69), 
although this is controversial (70).  Tang et al. (69) found that, following MDI induction 
of differentiation of 3T3-L1 cells, mitosis is induced, based on activation of 
cdk2/cyclinE/A, turnover of p27, hyperphosphorylation of Rb, and incorporation of 
radiolabeled thymidine into DNA.  Further, when cdk was inhibited with roscovitine, not 
only mitotsis, but also adipogenesis was blocked.  During mitotic clonal expansion, 
C/EBPβ undergoes phosphorylation changes necessary for its ability to bind DNA (see 
below) (69, 71).  After a lag period (~10hrs), C/EBPβ acquires the ability to bind to the 
promoters of C/EBPα and PPARγ genes.  Since mitotic clonal expansion is necessary for 
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differentiation, the lag time in the expression of C/EBPα and PPARγ is thought to be 
necessary because C/EBPα and PPARγ are both antimitotic (72, 73).   
 
Posttranslational Modifications Modulate Transcriptional Activation 
by C/EBPβ 
Phosphorylation of C/EBPβ is one mechanism to regulate its function.  
Phosphorylation occurs at multiple sites on C/EBPβ, and is mediated by different kinases 
(Fig 1.1).  In NIH-3T3 cells, expressed human C/EBPβ is phosphorylated at T235 (which 
corresponds to T188 in mouse) in the presence of Ras, and increases transcription of the 
Interleukin-6 (IL-6) promoter, a C/EBPβ target gene (74).  Lipopolysaccharide (LPS) 
increases Ras-induced phosphorylation of rat C/EBPβ at S64 (conserved in mouse).  This 
modification increases both IL-6 mRNA and protein in murine B lymphoblasts (75).  
Phosphorylation of rat C/EBPβ at S276 (conserved in mouse) mediated by Ca2+-
calmodulin-dependent protein kinase II (CaMKII) increases transactivation of a promoter 
that contains sites for C/EBPβ binding sites in pituitary cells (76).  Phosphorylation of rat 
C/EBPβ at S105 or of mouse C/EBPβ at T217 by p90 ribosomal S6 kinase stimulates 
proliferation in differentiated hepatocytes treated with TGFα (62).   
Phosphorylation of C/EBPβ can also be inhibitory.  Protein Kinase C-mediated 
phosphorylation at S240 of rat C/EBPβ is reported to attenuate DNA binding in 
hepatocytes (77).  PKC did not directly phosphorylate C/EBPβ in vitro, so it most likely 
induces a downstream kinase to directly phosphorylate C/EBPβ.  In resting osteoblasts, 
Glycogen Synthase Kinase (GSK)-3β mediates constitutive phosphorylation of rat 
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C/EBPβ at T189, S185, S181, and S177, which is inhibitory to C/EBPβ binding to DNA 
(78). 
 C/EBPβ is found exclusively in the nucleus of 3T3-L1 preadipocytes and 
adipocytes (71) and in 3T3-F442A preadipocytes (79).  In 3T3-F442A preadipocytes, 
C/EBPβ phosphorylated at T188 is induced to translocate to heterochromatin in response 
to GH (79).  In other cell lines, C/EBPβ can shuttle between the cytoplasm and the 
nucleus.  In PC12 cells, C/EBPβ was reported to translocate to the nucleus in a 
cAMP/PKA-dependent manner (80).  In DKO-1 colorectal cancer cells, the antioxidant 
pyrrolidinedithiocarbamate (PDTC) induces phosphorylation of C/EBPβ at S299, which 
is suggested to mediate translocation to the nucleus in a PKA-dependent manner (81).  In 
mouse hepatocytes, Tumor Necrosis Factor (TNF) α induces C/EBPβ phosphorylation at 
S239, which then facilitates CRM1-mediated nuclear export (82).  S239 lies in “motif A” 
(residues 226-246), which has been reported to function as a nuclear localization signal 
(83).  
 
C/EBPβ contributes to GH-mediated activation of c-fos   
The adipogenic conversion of 3T3-F442A preadipocytes is dependent on growth 
hormone (GH) (14).  C/EBPβ protein levels increase in response to GH in 3T3-F442A 
preadipocytes (84).  C/EBPβ is also a critical mediator of the activation by GH of c-fos, a 
proto-oncogene target of C/EBPβ (85-88).  When C/EBPβ is decreased by siRNA 
directed against C/EBPβ in either 3T3-F442A preadipocytes or Chinese Hamster Ovary 
(CHO) cells, GH can no longer mediate activation of c-fos (89).  Thus, C/EBPβ 
contributes to GH-mediated activation of c-fos.   
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The importance of the phosphorylation of C/EBPβ in GH-stimulated transcription 
is suggested by reports of multiple changes in the phosphorylation state of C/EBPβ in 
response to GH (Fig. 1.1).  Isoelectric focusing identified at least six distinct 
phosphorylated forms of C/EBPβ that are regulated by GH in 3T3-F442A cells (90).  A 
Mitogen-Activated Protein Kinase (MAPK) substrate site at T235 in human C/EBPβ 
(74), which corresponds to T188 in murine C/EBPβ, is rapidly and transiently 
phosphorylated in response to GH in an Extracellular signal Regulated Kinase (ERK) 
1/2-dependent manner; such phosphorylation alters its ability to activate transcription of 
target genes such as c-fos (90).  Mutation at that MAPK phosphorylation site of C/EBPβ 
almost completely abrogates the stimulation of the c-fos promoter in response to GH, 
indicating that phosphorylation at the MAPK substrate site is required for GH to activate 
c-fos.  
It is notable that while phosphorylation of C/EBPβ at T188 is rapid and transient, 
dephosphorylation of C/EBPβ at aGSK-3 substrate site (91) may occur only after 60 
minutes of GH treatment.  The delayed dephosphorylation may mediate attenuation of c-
fos transcription; it is dependent on activation by GH of phosphatidylinositol 3-Kinase 
(PI3K) and downstream AKT, which leads to inhibition of GSK-3 activity.  Thus, 
regulation by GH of the phosphorylation state of C/EBPβ, mediated by MAPK and PI3K-
AKT signaling cascades, is an important component of the mechanisms of GH-stimulated 
transcription of c-fos.  
SUMOylation of C/EBPβ may also contribute to GH-mediated activation of c-fos.  
SUMOylation is a posttranslational modification which is often associated with negative 
regulation of transcription (92, 93).  SUMOylation involves the conjugation of members 
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of the Small Ubiquitin-Like MOdifier (SUMO) family to acceptor lysine residues in 
target proteins (94).  Lysine 133 in murine C/EBPβ is SUMOylated (95-97).  Previous 
data indicate that mutation of C/EBPβ at K133 elevates basal c-fos transcription to a level 
where it cannot be further stimulated by GH (97), opening the possibility that 
deSUMOylation, and consequent relief of an inhibitory effect of SUMO, may contribute 
to the ability of C/EBPβ to activate transcription in response to GH. 
 
Phosphorylation of C/EBPβ and adipogenesis  
Phosphorylation of C/EBPβ at the MAPK/ERK substrate site T188 increases during 
adipogenesis in 3T3-L1 cells (98, 99).  Phosphorylation at this site is detected within 4 
hours after adipose differentiation commences in response to MDI medium, which is 
when MAPK is present and active (phosphorylated) within the nucleus of 3T3-L1 cells 
(99).   It has also recently been found that although T188 is initially phosphorylated by 
MAPK, phosphorylation at this site is maintained by cdk2 (100).  It is not until ~10 hrs 
after differentiation commences that C/EBPβ is phosphorylated at the GSK-3 sites T179 
and S184, concurrent with the timing of translocation of GSK3 to the nucleus.  This 
GSK3-mediated phosphorylation of C/EBPβ, which is dependent on prior 
phosphorylation at T188, then promotes maximal DNA-binding by C/EBPβ on promoters 
of adipocyte genes such as C/EBPα and aP2 (99).  In agreement with these studies, Park 
et al. observed that phosphorylation of C/EBPβ at T188 is required to induce expression 
of C/EBPα and adiponectin (98).  Thus, phosphorylation of C/EBPβ appears to 







Fig 1.2.  Acetylation of a lysine residue.  Shown are both a nonacetylated and acetylaed 
lysine residue.  Adapted from Li et al. (104). 
 























Acetylation of Nuclear Proteins 
 
In addition to phosphorylation and sumoylation, a growing list of modifications, 
including acetylation, methylation, and ubiquitination, regulate the transcriptional 
regulatory potential of multiple nuclear proteins (101).  In the case of histone acetylation, 
acetyltransferases add an acetyl group to the ε-amino group of multiple lysine side chains 
in the N-terminal tail region (Fig 1.2).  Acetylation is associated with chromatin 
remodeling which makes DNA more accessible to the transcriptional regulatory 
machinery (102).   Histone methylation on arginines is usually involved in gene 
activation, while histone methylation on lysines is usually repressive (101).  Histone 
ubiquitination on lysines may also be involved in modulating gene activity.  
Combinations of such modifications, now considered to serve as a “histone code,” further 
modulate chromatin structure (103). 
The acetylation state of nuclear proteins is highly susceptible to regulation by 
histone acetyltransferases (HATs) and/or histone deacetylases (HDACs).  Although the 
original terminology referred to these as “histone” enzymes, they are now recognized to 
modulate the addition of acetyl groups to lysines of a wide array of non-histone substrates 
as well.  Unlike phosphorylating kinases, there is no reported evidence of “acetylation 
cascades”, or the consecutive procession of acetylase activity, to modify a biological 





Acetyltransferases   
Several families of protein acetylasetransferases are exemplified by CBP/p300, 
P300/CBP Associated Factor / General Control Nonderepressible-5 (PCAF/GCN5), 
TATA box binding protein Associated Factor (TAF) II 250 (TAFII250), Steroid Receptor 
Coactivator (SRC) 1, and MOZ (Monocytic leukemia Zinc finger protein (105).  Two 
well-studied examples of acetyltransferases are CBP and the highly homologous p300 
(106, 107).  CBP and p300 were initially identified through their respective associations 
with transcription factor CREB and the viral protein E1A (108-110).  In humans, 
Rubenstein-Taybi Syndrome is associated with CBP heterozygosity (111-113).  
Rubenstein-Taybi Syndrome is a developmental disorder characterized by mental 
retardation, unusual facial appearance and broad digits.  p300 heterozygosity has also 
been reported in tumor tissue from several carcinoma patients (111, 113).  In mice, CBP 
or p300 homozygosity is embryonic lethal (112, 114).  Because of the diversity of defects 
and the many binding partners of these coactivators, it has been difficult to pinpoint any 
one reason for the lethality.  
In cultured cells, CBP and p300 are localized only in the nucleus (110, 112).  
However, in tissue, CBP and p300 can be found in both the nucleus and the cytoplasm.  
For example, in murine notochord cells, p300 translocates from the cytoplasm to the 
nucleus during embryonic development (112).  In primordial ovarian follicles, CBP and 
p300 are initially found in the cytoplasm of oocytes, but p300 and CBP move to the 
nucleus during later growth stages (115).  Cytoplasmic localization is not surprising 
considering that these acetyltransferases have been found to acetylate both cytoplasmic 
and nuclear substrates.   
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Interestingly, during adipose conversion of 3T3-L1 and 3T3-F442A cells, p300 
levels increase (116) and p300/CBP knockdown suppresses differentiation of 3T3-L1 
cells (117).  Further, p300 has been found to enhance C/EBPα- (118) and PPARγ-
mediated (117, 119) transcription of adipogenic target genes.  These data indicate that 
p300 contributes to adipose differentiation. 
 
Deacetylases   
In contrast to acetylases, HDACs catalyze removal of acetyl groups from substrates.  
HDACs are divided into three classes (120, 121):  Class I HDACs, which include 
HDACs 1, 2, 3, 8, and most likely 11, resemble yeast deacetylase RPD3 in terms of 
sequence similarity, and are localized primarily in the nucleus.  HDAC1 and HDAC2 are 
part of high-molecular-weight corepressor complexes, Sin3 and NuRD-Mi-2.  HDAC3 is 
a component of N-CoR and SMRT corepressor complexes.  Class II HDACs, 4, 7, 9, and 
10, resemble yeast deacetylase HDA1, and exhibit tissue-specific expression.  Class III 
HDACs are NAD+-dependent, and are the least characterized of the HDACs.  There are 
several classes of HDAC inhibitors.  Trichostatin A (TSA) inhibits class I and II HDACs 
by directly binding to their catalytic domain, and nicotinamide inhibits class III HDACs 
by promoting a base-exchange reaction with NAD+ so that it can no longer act as a 
cofactor in HDAC III-mediated deacetylation (122).  Use of HDAC inhibitors has 
become an emerging approach to treating proliferative disorders such as cancers (120, 
123).  
During adipose conversion of 3T3-L1 and 3T3-F442A cells, HDAC levels 
decrease (116).  Further, HDAC1 overexpression decreases adipocyte conversion in 3T3-
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L1 cells (116, 124).  Recently, knockdown by siRNA of Sirt2, a class III HDAC, was 
reported to promote 3T3-L1 adipose differentiation, while overexpression of Sirt2 
impaired it (125).  Sirt2, which is cytoplasmic, increases acetylation of Foxo1, which in 
turn increases Foxo1 phosphorylation, and excludes it from the nucleus.  This is 
postulated to contribute to the observed increase in adipose differentiation since Foxo1 is 
known to bind and repress the PPARγ promoter (126).  These studies suggest that overall 
HDAC levels decrease during adipose conversion, which is consistent with the increase 
observed in overall acetyltransferase levels.      
As reported in the literature, the consequences of inhibiting HDACs during 
adipose differentiation have been inconsistent.  Lagace and Nachtigal (127) reported that 
when 3T3-L1 cells are treated with TSA (1-10nM) or valproic acid (1mM, an HDAC 
inhibitor in the same family as sodium butyrate), there is an impairment in adipose 
differentiation, as well as a decrease in the expression of PPARγ and C/EBPα.  This 
decrease in differentiation was not surprising in light of data that mitotic clonal expansion 
is an early step in adipose differentiation (128), and that TSA blocks both cell cycle 
progression in HeLa cells (129) and proliferation in hepatocellular carcinoma cells (130). 
In contrast, others report an increase in adipose differentiation with HDAC 
inhibition (116, 124, 131).  TSA (400nM) or valproic acid (10mM) increased adipose 
differentiation in 3T3-L1 cells, but only in the absence of dexamethasone; no 
enhancement was observed for adipose differentiation in the presence of dexamethasone 
(124).  With 1.5mM valproic acid treatment, Fajas et al. (131) demonstrated an increase 
in adipocyte differentiation in 3T3-L1 cells.  Yoo et al. (116) observed an increase in 
3T3-L1 differentiation with sodium butyrate (500μM).  These studies suggest that 
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acetylation-mediated chromatin remodeling is necessary for induction of important genes 
for adipose differentiation.  Thus, the mechanism of how HDACs, and associated 
changes in acetylation of their substrates, regulate adipose differentiation is unclear at 
present.  
 
Functional Consequences of Acetylation of Transcription Factors 
 
Acetylation of nuclear proteins was first detected in histones and is viewed as a 
part of a mechanism allowing DNA to become accessible to transcription regulatory 
machinery (132, 133).  It is now recognized that many cellular proteins are regulated by 
acetylation.  In the nucleus, acetylation of a growing number of transcription factors is 
reported to have broad impact on their function.  For example, the acetylation of the 
tumor suppressor p53 stabilizes it by preventing its ubiquitination by Mdm2, thereby 
allowing p53 to enter the nucleus to activate target genes (104).  Acetylation of p53 at 
lysines 320, 373, and 382 increases its binding to cognate DNA (134, 135).  Acetylation 
is also reported to increase nuclear localization of, and thus transcription activation by, 
NF-κB, by weakening its interaction with IκBα, which sequesters NF-κB in the 
cytoplasm (136).  Acetylation of GATA-1 was found to increase its binding to DNA, 
thereby stimulating GATA-1 dependent transcription (137).   
Other functional consequences of acetylation include promoting interaction of the 
nuclear import factor importin-α with importin-β (138).  Ku70 is unable to bind and 
sequester pro-apoptotic BAX when Ku70 is acetylated (139).  Acetylation in the DNA-
binding domain of HMGI(Y), a complex required for enhancesome assembly, is 
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inhibitory, decreasing its DNA-binding ability and weakening its transcriptional potency 
(105, 140).  Acetylation has also been observed to increase the stability of E2F1.  P/CAF, 
but not P/CAF with the HAT domain mutated, acetylates and concomitantly increases the 
stability of E2F1 by an unknown mechanism (141).  Thus, acetylation can modify the 
function of a variety of cellular proteins by altering binding to DNA, binding to other 
proteins, and regulating degradation. 
 
Aims of Thesis 
 
Control of transcription by transcription factors involved in adipose 
differentiation and potentially obesity, is an area of study of increasing interest as the 
prevalence of obesity rises.  One mode to control transcription factors is through 
posttranslational modifications such as acetylation, which we now recognize as a 
powerful determinant of transcription factor action.  This thesis explores the acetylation 
of C/EBPβ and its functional consequences, particularly in the regulation of target genes 
involved in adipogenesis. 
Chapter II presents studies conducted to demonstrate the acetylation of C/EBPβ 
by p300 and P/CAF.  Mapping studies were carried out to pinpoint acetylated amino 
acids within the C/EBPβ sequence.  These studies provide the foundation for further 
studies as to the functional consequences of acetylation of C/EBPβ at these lysines.  
Since C/EBPβ is a transcription factor, whether acetylation of C/EBPβ alters 
transcriptional activation of the target gene c-fos was examined.  c-fos has proven to be 
an excellent model gene not only of C/EBPβ transcriptional potential, but also of GH-
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mediated gene activation.  Whether acetylation and phosphorylation of C/EBPβ work in 
coordination was also investigated.  
C/EBPβ is also an early inducer of adipogenesis (10).  It induces the expression of 
the master regulators of adipogenesis, C/EBPα and PPARγ (3).  Chapter III explores 
whether endogenous C/EBPβ is acetylated in adipocytes, and what roles acetylation of 
C/EBPβ may play during adipogenesis, particularly in the activation of key regulators of 
adipogenesis.  Further, the deacetylation of C/EBPβ by HDACs was examined to 
characterize the dynamic regulation of the acetylation of C/EBPβ. 
Acetylation of C/EBPβ is likely to be one component of a complicated puzzle that 
contributes to adipogenesis.  Regulation of adipose differentiation involves control of 
many genes to convert preadipocytes to adipocytes.  Multiple posttranslational 
modifications of regulatory proteins most certainly contribute to this control.  Ultimately, 
targeting these posttranslational modifications may lead to treatment options to overcome 
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